%0 Journal Article %T Comparison of Rheumatoid Arthritis Patients' 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates. %+ Université de Picardie Jules Verne (UPJV) %+ CHU Amiens-Picardie %+ Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV) %+ HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 (HEMATIM) %A Diep, Laetitia %A Barbier, Vincent %A Doussière, Marie %A Touboul, Estelle %A Jesson, Claire %A Deprez, Valentine %A Sobhy-Danial, Jean-Marc %A Fardellone, Patrice %A Goëb, Vincent %< avec comité de lecture %J Journal of clinical medicine %V 11 %N 20 %8 2022 %D 2022 %R 10.3390/jcm11205978 %M 36294300 %K abatacept %K infliximab %K persistence %K retention %K rheumatoid arthritis %K tocilizumab %Z Life Sciences [q-bio]/Human health and pathologyJournal articles %X BACKGROUND: Drug persistence reflects an agent's efficacy and safety in routine practice. This study was undertaken to compare the 2-year persistence rates of three biologic disease-modifying antirheumatic drugs (bDMARDs) used to treat rheumatoid arthritis (RA) and to describe their efficacy and safety profiles. METHODS: This retrospective, observational, single-center study included RA patients who had received at least one intravenous dose of infliximab, abatacept, and/or tocilizumab. Two-year drug persistence was estimated using the Kaplan-Meier method. Efficacy profiles were assessed as changes of Disease-Activity Score-28 (DAS28)-based EULAR-criteria responses. RESULTS: The infliximab, abatacept, and tocilizumab groups included 40, 72, and 93 patients, respectively. Their respective 2-year persistence rates were similar: 55.0%, 45.8%, and 62.4%. Tocilizumab recipients benefited from greater improvement than those given infliximab (p = 0.0005) or abatacept (p < 0.0001). For all groups combined, 93.1% of patients obtained good or moderate EULAR responses. CONCLUSIONS: Even if this retrospective work includes different biases (lack of data, recruitment bias, etc.), it highlights that the 2-year persistence rates for infliximab, abatacept, and tocilizumab in daily practice did not differ significantly, thereby confirming the long-term efficacies of these three bDMARDs. However, tocilizumab was associated with more significant DAS28 improvement at 2 years than infliximab and abatacept. %G English %L hal-03838381 %U https://u-picardie.hal.science/hal-03838381 %~ UNIV-PICARDIE %~ U-PICARDIE %~ MP3CV %~ HEMATIM %~ TEST3-HALCNRS